Herding an atypical syndicate

How Caribou aligned its series B syndicate with its CRISPR business areas

Unlike its gene editing peers that are going deep into therapeutics, Caribou Biosciences Inc. has been going wide, exploring numerous sectors where its CRISPR-Cas9 technology could be applied. With last week's $30 million series B round, Caribou has recruited

Read the full 397 word article

User Sign In